191 -2 (88) 2026 - Artikova S.G., Isakova D.Z. - ALGORITHM FOR ASSESSING CARDIOMETABOLIC RISK IN PATIENTS WITH METABOLICALLY ASSOCIATED FATTY LIVER DISEASE

ALGORITHM FOR ASSESSING CARDIOMETABOLIC RISK IN PATIENTS WITH METABOLICALLY ASSOCIATED FATTY LIVER DISEASE

Artikova S.G. - Andijan State Medical Institute

Isakova D.Z. - Andijan State Medical Institute

Valieva Z.S. - Andijan State Medical Institute

Yunusova Z.V. - Andijan State Medical Institute

Resume

This article addresses contemporary approaches to the assessment of cardiometabolic risk in patients with metabolically associated fatty liver disease (MAFLD). MAFLD is closely linked to insulin resistance, dyslipidemia, arterial hypertension, and type 2 diabetes mellitus, significantly increasing the risk of cardiovascular complications. An algorithm for comprehensive cardiometabolic risk assessment is proposed, based on the integrated analysis of clinical and anamnestic data, anthropometric parameters, and laboratory and instrumental findings. The application of this algorithm enables effective risk stratification, early identification of high-risk patients, and the development of individualized preventive and therapeutic strategies. The findings of this study may be useful for clinical practice and contribute to reducing cardiovascular morbidity in patients with MAFLD.

Keywords: metabolically associated fatty liver disease, cardiometabolic risk, insulin resistance, metabolic syndrome, cardiovascular diseases, risk assessment algorithm, dyslipidemia.

First page

1044

Last page

1049

For citation:Artikova S.G., Isakova D.Z., Valieva Z.S., Yunusova Z.V. - ALGORITHM FOR ASSESSING CARDIOMETABOLIC RISK IN PATIENTS WITH METABOLICALLY ASSOCIATED FATTY LIVER DISEASE//New Day in Medicine 2(88)2026 1044-1049 https://newdayworldmedicine.com/en/new_day_medicine/2-88-2026

List of References

  1. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature Reviews Gastroenterology Hepatology. 2013;10 (6):330-344. DOI: 10.1038/nrgastro.2013.41.
  2. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987-1000. DOI: 10.1002/hep.20920.
  3. Byrne C.D., Targher G. NAFLD: A multisystem disease. Journal of Hepatology. 2015;62(1):47-64. DOI: 10.1016/j.jhep.2014.12.012.
  4. Dyson J.K., Anstee Q.M., McPherson S. Non-alcoholic fatty liver disease: A practical approach to diagnosis and staging. Frontline Gastroenterology. 2014;5(3):211-218. DOI: 10.1136/flgastro-2013-100403.
  5. Eslam M., Newsome P.N., Sarin S.K. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology. 2020;73(1):202-209. DOI: 10.1016/j.jhep.2020.03.039.
  6. Friedman S.L. et al. (2018). Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine, 2018;24(7):908-922.
  7. Loomba R., Adams L.A. (2020). Advances in NAFLD therapeutics. // Nature Reviews Gastroenterology Hepatology, 2020;17(1):11-13.
  8. Loomba R. et al. (2021). Emerging mechanisms and potential therapeutics for NAFLD-related fibrosis. // Hepatology 2021;74(2):616-629.
  9. Mantovani A., Byrne C.D., Scorletti E. et al. Complications and outcomes of NAFLD and NASH. Nature Reviews Gastroenterology // Hepatology. 2021;18(4):257-267. DOI: 10.1038/s41575-020-00393-9.
  10. Tilg H. et al. (2019). NAFLD and diabetes mellitus. //Nature Reviews Gastroenterology Hepatology, 2019;16(4):238-250.
  11. Younossi Z.M. et al. (2021). Nonalcoholic fatty liver disease: Assessment of scientific gaps and clinical needs. // Journal of Hepatology 2021;74(6):1402-1415.
  12. Younossi Z.M., Golabi P., de Avila L. et al. The global epidemiology of NAFLD and NASH. // Hepatology 2020;72(1):73-83. DOI: 10.1002/hep.29367.

    file

    download